High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia

Annals of Oncology : Official Journal of the European Society for Medical Oncology
T KarakasL Bergmann

Abstract

The bcl-2 oncoprotein is suggested to be directly involved in the emergence of drug resistance by disrupting or delaying the apoptotic program and promoting tumor survival. In order to define the clinical relevance of the bcl-2 mRNA expression in acute myeloid leukemia (AML) and its correlation to therapy outcome and prognosis, we analyzed 219 AML bone marrow (BM) samples, including 119 patients with de novo AML at presentation, 37 with AML following myelodysplastic syndrome (MDS), as well as 42 BM samples of AML in relapse and 21 in complete remission (CR) using RT-PCR. For performing quantitative measurements of bcl-2 mRNA, we developed a quantitative RT-PCR. Bcl-2 mRNA was detectable in 133 of 156 (84%) patients at diagnosis and 40 of 42 (95%) at relapse. AML patients with high bcl-2 mRNA expression achieved lower CR rates than those with no or low expression. Concerning the long-term outcome, the overall (OS) and disease-free survival (DFS) was significantly worse in AML patients with high expression levels of bcl-2 mRNA. The three-year OS for all newly diagnosed AML patients was 49% and 10% (P = 0.028), respectively, and 71% and 15% (P = 0.0004) for patients < 60 years. Comparable significant differences were observed for ...Continue Reading

Citations

Nov 25, 2000·British Journal of Haematology·Y L OngA E Irvine
Dec 14, 2002·Blood·Mustafa BenekliMeir Wetzler
Aug 13, 2002·Hematology·Alexandra E IrvineYong-Lee Ong
Sep 24, 2005·Hematological Oncology·Kaishan LiuChristian Andreas Schmidt
Jan 4, 2006·International Journal of Immunopathology and Pharmacology·F CipolloneA Mezzetti
Jul 18, 2006·BMC Bioinformatics·Pavlos Pavlidis, Panayiota Poirazi
Sep 24, 2011·Advances in Hematology·Flora TzifiAndreas Scorilas
Nov 24, 2012·Expert Opinion on Therapeutic Targets·Shibu ThomasPaul B Fisher
Jan 5, 2019·Blood·Laura C Michaelis
May 6, 2020·Investigational New Drugs·Małgorzata Opydo-ChanekLidia Mazur
Mar 13, 2001·Leukemia·D M O'Gorman, T G Cotter
Mar 15, 2006·Critical Reviews in Clinical Laboratory Sciences·Hellinida Thomadaki, Andreas Scorilas
Jan 13, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Dimitrios Korbakis, Andreas Scorilas
Sep 14, 2013·Oncotarget·Niraj M ShahDavid J MacEwan
Nov 25, 2000·British Journal of Haematology·C AdidaH Dombret
Aug 15, 2009·Current Oncology Reports·Amir T Fathi, Judith E Karp
Jun 2, 2010·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali FendriAndreas Scorilas
Apr 5, 2013·Pediatric Blood & Cancer·Surender Kumar SharawatSameer Bakhshi
Aug 7, 2002·Antisense & Nucleic Acid Drug Development·Richard J KlasaStanley R Frankel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.